2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1693

High Prevalence of Cardiac Disease in Patients with Ankylosing Spondylitis
Abstract Number: 1694

All-Cause Mortality and Malignancies in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Abstract Number: 1695

Fatigue May be Independently Active at a Certain Part of Spondyloarthritis Patients: Hur-BIO Real Life Results
Abstract Number: 1696

Score Classification Underestimates the Real Cardiovascular Risk in Psoriatic Arthritis Patients
Abstract Number: 1697

Obstructive Sleep Apnea and Fatigue in Inflammatory Arthritis Patients Taking TNF-Inhibitors
Abstract Number: 1698

High Prevalence of Traditional Cardiovascular Risk Factors in an Ankylosing Spondylitis Cohort
Abstract Number: 1699

Obesity and Pediatric Psoriatic Arthritis
Abstract Number: 1700

Subclinical Atherosclerosis in Ankylosing Spondylitis. Does It Really Exist and Which Are the Effects of Treatments? a Systematic Review
Abstract Number: 1701

Long Term Outcome of Total Hip Replacement in Patients with Ankylosing Spondylitis
Abstract Number: 1702

Osteoporosis in Psoriatic Arthritis
Abstract Number: 1703

Obesity Is Related with Active State in Psoriatic Arthritis and Rheumatoid Arthritis but Not Ankylosing Spondylitis at Real Life Biological Cohort
Abstract Number: 1704

Prevalence of Obesity and Metabolic Syndrome in Patients with Axial Spondyloarthritis
Abstract Number: 1705

Acute Anterior Uveitis in Ankylosing Spondylitis: Association with Inflammatory Bowel Disease and Psoriasis Independent of HLA-B27
Abstract Number: 1706

Prevalence and Factors Associated with Non-Traumatic Vertebral Fractures in Psoriatic Arthritis
Abstract Number: 1707

Comorbidity Burden and Medication Use Among Patients with Psoriatic Arthritis in the US

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].